Full Product Name
F11 siRNA (Human)
Product Synonym Names
Coagulation factor XI; FXI; Plasma thromboplastin antecedent; PTA
Product Gene Name
F11 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for P03951
Specificity
F11 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human F11 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of F11 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
F11 sirna
siRNA to inhibit F11 expression using RNA interference
Applications Tested/Suitable for F11 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for F11. It may not necessarily be applicable to this product.
NCBI Accession #
NP_000119.1
[Other Products]
NCBI GenBank Nucleotide #
NM_000128.3
[Other Products]
UniProt Primary Accession #
P03951
[Other Products]
UniProt Secondary Accession #
Q4W5C2; Q9Y495; D3DP64[Other Products]
UniProt Related Accession #
P03951[Other Products]
Molecular Weight
63,840 Da
NCBI Official Full Name
coagulation factor XI
NCBI Official Synonym Full Names
coagulation factor XI
NCBI Official Symbol
F11??[Similar Products]
NCBI Official Synonym Symbols
FXI
??[Similar Products]
NCBI Protein Information
coagulation factor XI
UniProt Protein Name
Coagulation factor XI
UniProt Synonym Protein Names
Plasma thromboplastin antecedent; PTA
Protein Family
Coagulation factor
UniProt Gene Name
F11??[Similar Products]
UniProt Synonym Gene Names
FXI; PTA??[Similar Products]
UniProt Entry Name
FA11_HUMAN
NCBI Summary for F11
This gene encodes coagulation factor XI of the blood coagulation cascade. This protein is present in plasma as a zymogen, which is a unique plasma coagulation enzyme because it exists as a homodimer consisting of two identical polypeptide chains linked by disulfide bonds. During activation of the plasma factor XI, an internal peptide bond is cleaved by factor XIIa (or XII) in each of the two chains, resulting in activated factor XIa, a serine protease composed of two heavy and two light chains held together by disulfide bonds. This activated plasma factor XI triggers the middle phase of the intrisic pathway of blood coagulation by activating factor IX. Defects in this factor lead to Rosenthal syndrome, a blood coagulation abnormality. [provided by RefSeq, Jul 2008]
UniProt Comments for F11
F11: Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. Defects in F11 are the cause of factor XI deficiency (FA11D); also known as plasma thromboplastin antecedent deficiency or Rosenthal syndrome. It is a hemorrhagic disease characterized by reduced levels and activity of factor XI resulting in moderate bleeding symptoms, usually occurring after trauma or surgery. Patients usually do not present spontaneous bleeding but women can present with menorrhagia. Hemorrhages are usually moderate. Belongs to the peptidase S1 family. Plasma kallikrein subfamily. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: Protease; Secreted, signal peptide; EC 3.4.21.27; Secreted
Chromosomal Location of Human Ortholog: 4q35
Cellular Component: extracellular space; membrane; extracellular region; plasma membrane
Molecular Function: heparin binding; protein binding; serine-type endopeptidase activity
Biological Process: positive regulation of fibrinolysis; proteolysis; blood coagulation; blood coagulation, intrinsic pathway; plasminogen activation
Disease: Factor Xi Deficiency
Research Articles on F11
1. This study presents the first application of a new thrombin generation based factor XIa assay.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
